StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30239% above fair value
$107.48−7.54 (-6.56%)

Close on Nov 16, 2026Market cap $7.40BP/E –Yield –

Rhythm Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Rhythm Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -85.6%. For fiscal 2025 it was -103.6%, against -200.3% the year before. The highest annual figure on record is -103.6% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-103.6%+96.7
FY2024Dec 31, 2024-200.3%+38.2
FY2023Dec 31, 2023-238.5%+527.7
FY2022Dec 31, 2022-766.2%+1440.9
FY2021Dec 31, 2021-2207.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-69.2%+27.0
Q1 FY2026Mar 31, 2026-92.6%+58.8
Q4 FY2025Dec 31, 2025-83.0%+20.5
Q3 FY2025Sep 30, 2025-103.1%+28.1
Q2 FY2025Jun 30, 2025-96.1%+14.8
Q1 FY2025Mar 31, 2025-151.4%+393.1
Q4 FY2024Dec 31, 2024-103.5%+68.3
Q3 FY2024Sep 30, 2024-131.2%+65.0
Q2 FY2024Jun 30, 2024-110.9%+132.0
Q1 FY2024Mar 31, 2024-544.4%−89.5
Q4 FY2023Dec 31, 2023-171.8%+311.6
Q3 FY2023Sep 30, 2023-196.2%+757.6
Q2 FY2023Jun 30, 2023-243.0%+253.4
Q1 FY2023Mar 31, 2023-455.0%+3067.3
Q4 FY2022Dec 31, 2022-483.4%+1875.7
Q3 FY2022Sep 30, 2022-953.8%+2461.3
Q2 FY2022Jun 30, 2022-496.4%+12419.3
Q1 FY2022Mar 31, 2022-3522.3%−128522.3
Q4 FY2021Dec 31, 2021-2359.2%–
Q3 FY2021Sep 30, 2021-3415.1%–
Q2 FY2021Jun 30, 2021-12915.7%–
Q1 FY2021Mar 31, 2021125000.0%–

More Rhythm Pharmaceuticals figures

See a number that looks wrong?